Compugen’s COM701 shows preliminary anti-tumor activity in ovarian cancer

Compugen announced publication of abstracts by ESMO-IO showing that at the time of abstract data cutoff, Compugen’s COM701 – anti-PVRIG – in dual and triple combination with nivolumab +/- BMS-986207 demonstrated preliminary anti-tumor activity and immune activation in platinum resistant ovarian cancer patients and was well tolerated. At the time of abstract data cutoff, COM701+ nivolumab + BMS-986207 demonstrated 20% overall response rate and 40% disease control rate in heavily pretreated patients with platinum resistant ovarian cancer and was well tolerated, with all responders remaining on therapy. CEO Anat Cohen-Dayag commented, "At ESMO-IO we will present encouraging preliminary anti-tumor activity supported by immune activation and favorable safety profile following the dual and triple blockade of PVRIG, PD-1 +/- TIGIT in platinum resistant ovarian cancer patients. The full data to be presented at the conference remain under embargo until December 6, 2022 and will contain longer follow up. We are looking forward to discussing this data along with our NSCLC data which will also be presented at ESMO-IO, in addition to our plans going forward, during our investor call on December 7, 2022."